TABLE 2.
Therapeutic strategies to target RAS indirectly in clinical trials
| Drug | Study phase | Disease setting | ClinicalTrials.gov identifier | Status |
|---|---|---|---|---|
| SOS1 inhibitors | ||||
| BI‐1701963 | I | Advanced solid tumors | NCT04111458 | Active, not recruiting |
| SHP2 inhibitors | ||||
| TNO155 | I | Advanced solid tumors | NCT03114319 | Recruiting |
| RMC‐4630 | I | Advanced solid tumors | NCT03634982 | Recruiting |
| JAB‐3068 | I/II | Advanced solid tumors | NCT04721223 | Recruiting |
| JAB‐3312 | I | Advanced solid tumors | NCT04045496 | Recruiting |
| BBP‐398 | I | Advanced solid tumors | NCT04528836 | Recruiting |
| ERAS‐601 | I | Advanced solid tumors | NCT04670679 | Recruiting |
| RLY‐1971 | I | Advanced solid tumors | NCT04252339 | Recruiting |
| SH3809 | I | Advanced solid tumors | NCT04843033 | Recruiting |
| RAF inhibitors | ||||
| Belvarafenib | I | Melanoma | NCT04835805 | Recruiting |
| LXH‐254 | I | Advanced solid tumors | NCT02607813 | Active, not recruiting |
| Lifirafenib | I/II | Advanced solid tumors | NCT03905148 | Recruiting |
| BGB‐3245 | I | Advanced solid tumors | NCT04249843 | Recruiting |
| TAK‐580 | I | Melanoma | NCT02723006 | Terminated |
| MEK inhibitors | ||||
| Binimetinib | III | Melanoma | NCT01763164 | Completed |
| Pimasertib | II | Melanoma | NCT01693068 | Completed |
| ERK inhibitors | ||||
| LY‐3214996 | I | Advanced solid tumors | NCT02857270 | Active, not recruiting |
| KO‐947 | I | Advanced solid tumors | NCT03051035 | Terminated |
Abbreviations: SOS1, son of sevenless 1; SHP2, Src homology‐2 domain‐containing protein tyrosine phosphatase 2; ERK, extracellular signal regulated kinase